

## Special Issue

# Targeting the NLRP3: From Novel Inhibitor Design to Clinic Trials and Therapeutic Applications

### Message from the Guest Editors

The NLRP3 inflammasome is a multiprotein complex that plays a critical role in mediating immune responses and maintaining homeostasis in the presence of pathogenic threats and danger signals. Dysregulated activation of NLRP3 has been implicated in a wide range of pathophysiological conditions, including metabolic disorders (diabetes, obesity, gout), cardiovascular diseases (atherosclerosis), neurological disorders (Alzheimer's disease, Parkinson's disease, multiple sclerosis), and autoinflammatory syndromes (CAPS), as well as various cancers and chronic inflammatory diseases. These associations underscore its importance as a promising therapeutic target. The development of highly selective, direct NLRP3 inhibitors has emerged as a major focus in drug discovery.

This Special Issue will showcase papers highlighting the latest advances in the development of direct NLRP3 inhibitors, particularly those that have entered clinical trials, as well as their emerging therapeutic applications.

---

### Guest Editors

Dr. Yiming Xu

Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA

Dr. Yana Cen

Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA

---

### Deadline for manuscript submissions

31 May 2026



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.8**  
**CiteScore 7.7**  
**Indexed in PubMed**



[mdpi.com/si/260760](https://mdpi.com/si/260760)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)